P2.13-38 Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients With Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1433
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Evaluation of a Tyrosine Kinase Peptide Microarray for Tyrosine Kinase Inhibitor Therapy Selection in Cancer

Experimental & Molecular Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy